Long-term use of traditional non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population

BMC Medicine

Volumn 3, Issue , 2005, Pages

  García Rodríquez, Luis A ^a   Gonzáles Pérez, Antonio ^a  

^a Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; STEROID;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INFORMATION RETRIEVAL; LONG TERM CARE; LOW DRUG DOSE; POPULATION RESEARCH; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RISK;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK;

EID: 29144489146     PISSN: 17417015     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-3-17     Document Type: Article

References (12)

1. FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004; 351(17):1709-1711.
2. National Institutes of Health, U.S. Department of Health and Human Services. NIH News: NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial. On NIH website [updated 2004 Dec 17]. [http://www.nih.gov/news/pr/dec2004/od-17.htm]
3. Solomon SD, McMurray JJ, Pfeffer MA, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005; 352:1071-1080
4. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of Rofecoxib, Celecoxib, and Other NSAIDs. Arch Int Med 2005; 165:978-984.
5. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366-1372.
6. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A: Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation 2004;109:3000-3006.
7. Walker AM: Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc., 1991.
8. García Rodríguez LA, Varas C, Patrono C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-387
9. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-481.
10. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471.
11. Reilly IA, FitzGerald GA: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
12. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.